S&P 500   3,337.95 (-0.33%)
DOW   27,327.81 (-0.22%)
QQQ   270.65 (-1.45%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
S&P 500   3,337.95 (-0.33%)
DOW   27,327.81 (-0.22%)
QQQ   270.65 (-1.45%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
S&P 500   3,337.95 (-0.33%)
DOW   27,327.81 (-0.22%)
QQQ   270.65 (-1.45%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
S&P 500   3,337.95 (-0.33%)
DOW   27,327.81 (-0.22%)
QQQ   270.65 (-1.45%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
Log in

NASDAQ:AUTLAutolus Therapeutics Stock Price, Forecast & News

$15.71
-0.42 (-2.60 %)
(As of 08/7/2020 02:03 PM ET)
Add
Compare
Today's Range
$15.60
Now: $15.71
$16.05
50-Day Range
$13.04
MA: $14.78
$16.30
52-Week Range
$3.00
Now: $15.71
$17.19
Volume8,871 shs
Average Volume246,893 shs
Market Capitalization$706.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.97
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Read More
Autolus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUTL
CUSIPN/A
CIKN/A
Phone44-20-3829-6230

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 million
Book Value$5.67 per share

Profitability

Net Income$-123,850,000.00
Net Margins-9,870.67%

Miscellaneous

EmployeesN/A
Market Cap$706.64 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$15.71
-0.42 (-2.60 %)
(As of 08/7/2020 02:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

How has Autolus Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AUTL shares have increased by 132.1% and is now trading at $15.71.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Autolus Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Autolus Therapeutics
.

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Autolus Therapeutics
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics Ltd - (NASDAQ:AUTL) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. Autolus Therapeutics had a negative net margin of 9,870.67% and a negative return on equity of 45.59%.
View Autolus Therapeutics' earnings history
.

What price target have analysts set for AUTL?

7 brokers have issued twelve-month price objectives for Autolus Therapeutics' stock. Their forecasts range from $24.00 to $38.00. On average, they anticipate Autolus Therapeutics' share price to reach $27.33 in the next year. This suggests a possible upside of 74.0% from the stock's current price.
View analysts' price targets for Autolus Therapeutics
.

What are Wall Street analysts saying about Autolus Therapeutics stock?

Here are some recent quotes from research analysts about Autolus Therapeutics stock:
  • 1. According to Zacks Investment Research, "Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. " (7/7/2020)
  • 2. HC Wainwright analysts commented, "Our $24 price target, is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model, and reflects the recent dilution from the secondary offering. Our DCF is based on: beta of 1.50, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.4%, and tax rate of 15% beginning in FY 2028. Our rNPV for: (1) AUTO3 is $17; (2) AUTO1 is $4; and (3) AUTO4 is $3, which are derived from probability adjusted peak sales of: (1) $432M; (2) $150M; and (3) $96M, respectively." (9/12/2019)

Has Autolus Therapeutics been receiving favorable news coverage?

News headlines about AUTL stock have been trending positive on Friday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Autolus Therapeutics earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Autolus Therapeutics
.

Who are some of Autolus Therapeutics' key competitors?

What other stocks do shareholders of Autolus Therapeutics own?

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the following people:
  • Dr. Christian Martin Itin, Chairman & CEO (Age 55)
  • Dr. Martin Pulé, Founder, Sr. VP & Chief Scientific Officer (Age 47)
  • Mr. Andrew J. Oakley, CFO & Sr. VP (Age 57)
  • Mr. Christopher Vann, Sr. VP & COO (Age 55)
  • Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 54)

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include New York State Common Retirement Fund (0.06%) and UBS Group AG (0.01%).

Which major investors are buying Autolus Therapeutics stock?

AUTL stock was bought by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, and UBS Group AG.

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $15.71.

How big of a company is Autolus Therapeutics?

Autolus Therapeutics has a market capitalization of $706.64 million and generates $2.91 million in revenue each year. The company earns $-123,850,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is www.autolus.com.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.